Table 1.
Current use and sales of anthypertensive drugs (based on IMS-data for the year 2000)
| Total use (DDDs*/1000 inhabitants/day) | Total sales (in US$1000, ex-manufacturer) | Average price per DDD* | Proportion for hypertension | |
| Canada | ||||
| Alpha blocking agents | 3.6 | 18 744 | $0.46 | 45 % |
| Thiazides | 26.8 | 13 406 | $0.04 | 87 % |
| Beta blocking agents | 21.9 | 88 518 | $0.35 | 52 % |
| Calcium channel blockers | 39.2 | 265 497 | $0.59 | 71 % |
| ACE-inhibitors‡ | 58.0 | 279 688 | $0.42 | 73 % |
| Angiotensin II antagonists‡ | 10.6 | 69 055 | $0.57 | 90 % |
| Total | 160.1 | 734 908 | ||
| France | ||||
| Alpha blocking agents | 4.3 | 60 815 | $0.65 | 74 % |
| Thiazides | 9.9 | 55 224 | $0.26 | 90 % |
| Beta blocking agents | 41.7 | 203 074 | $0.22 | 67 % |
| Calcium channel blockers | 38.2 | 297 152 | $0.36 | 72 % |
| ACE-inhibitors ‡ | 35.0 | 276 846 | $0.37 | 75 % |
| Angiotensin II antagonists ‡ | 15.2 | 178 691 | $0.54 | 92 % |
| Total | 144.3 | 1 071 802 | ||
| Germany | ||||
| Alpha blocking agents | 5.0 | 84 900 | $0.56 | 74 % |
| Thiazides | 23.3 | 72 444 | $0.10 | 54 % |
| Beta blocking agents | 40.6 | 350 569 | $0.29 | 66 % |
| Calcium channel blockers | 48.4 | 365 760 | $0.25 | 62 % |
| ACE-inhibitors ‡ | 47.7 | 307 873 | $0.21 | 75 % |
| Angiotensin II antagonists ‡ | 13.1 | 182 211 | $0.46 | 87 % |
| Total | 178.1 | 1 363 757 | ||
| Norway | ||||
| Alpha blocking agents | 10.5 | 7 590 | $0.44 | 89 %† |
| Thiazides | 9.1 | 620 | $0.04 | 79 %† |
| Beta blocking agents | 32.6 | 16 528 | $0.31 | 50 %† |
| Calcium channel blockers | 50.4 | 26 753 | $0.32 | 60 %† |
| ACE-inhibitors‡ | 35.0 | 17 997 | $0.31 | 65 %† |
| Angiotensin II antagonists‡ | 15.6 | 14 067 | $0.55 | 90 %† |
| Total | 153.2 | 83 555 | ||
| UK | ||||
| Alpha blocking agents | 6.1 | 112 562 | $0.85 | 64 % |
| Thiazides | 38.8 | 51 135 | $0.06 | 69 % |
| Beta blocking agents | 28.7 | 165 872 | $0.27 | 47 % |
| Calcium channel blockers | 46.6 | 410 793 | $0.41 | 55 % |
| ACE-inhibitors ‡ | 42.6 | 355 284 | $0.38 | 56 % |
| Angiotensin II antagonists ‡ | 6.1 | 105 237 | $0.79 | 65 % |
| Total | 168.9 | 1 200 883 | ||
| USA | ||||
| Alpha blocking agents | 11.6 | 702 423 | $0.59 | 48 % |
| Thiazides | 32.8 | 293 894 | $0.09 | 81 % |
| Beta blocking agents | 25.4 | 1 464 213 | $0.56 | 53 % |
| Calcium channel blockers | 57.5 | 4 302 075 | $0.73 | 76 % |
| ACE-inhibitors ‡ | 73.2 | 3 345 469 | $0.44 | 74 % |
| Angiotensin II antagonists ‡ | 12.7 | 1 001 629 | $0.77 | 85 % |
| Total | 213.2 | 11 109 703 | ||
*Defined daily dosages; †Based on data from 1994–96; ‡ Combinations with thiazides not included